616 F. App'x 442
2d Cir.2015Background
- Lead Plaintiff Paige sues on behalf of a putative class of Magnum Hunter investors arising from 2012–2013 securities purchases.
- Plaintiffs assert Exchange Act §10(b) claims against Magnum Hunter executives (Evans, Ormand, Krueger, Smith, Ferguson) and §20(a) control-person liability.
- Plaintiffs also assert Securities Act §§11 and 12 claims against executives, outside directors, and underwriters.
- Allegations center on misstatements about internal controls and subsequent restatements, including a November 2012 disclosure of material weaknesses.
- Court reviews a Rule 12(b)(6) dismissal de novo, evaluating whether plaintiffs stated a plausible scienter theory and timely Securities Act claims.
- District court dismissed the claims; on appeal the Second Circuit affirms, concluding lack of scienter and untimeliness under the statutes of limitations.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Did plaintiffs plead a strong inference of scienter under PSLRA? | Plaintiffs contend defendants consciously misrepresented control weaknesses. | Defendants argue disclosures and restatements show no cogent inference of scienter. | No strong inference of scienter; claims fail. |
| Are stock sales by Evans and Krueger indicia of motive and opportunity to defraud? | Sales show motive and opportunity to commit fraud. | Stock sales alone are insufficient to show motive/opportunity. | Insufficient to plead scienter. |
| Are Securities Act §11 and §12 claims timely? | Equitable tolling and discovery rule may save claims. | Claims untimely under discovery rule and statute; relation back and tolling fail. | Untimely; claims barred. |
| Does discovery rule abrogate the circuit's inquiry notice framework for §10(b) claims? | Merck supports discovery rule for Exchange Act claims. | Inquiry notice governs and discovery rule not adopted here. | Merck does not salvage; scienter not pleaded. |
| Do relation-back or equitable tolling doctrines save the claims? | DelCo’s standing could relate back; tolling due to discovery delays. | Standing and delays do not permit relation back or tolling in this context. | Neither doctrine cures the defects. |
Key Cases Cited
- ATSI Communications, Inc. v. Shaar Fund, Ltd., 493 F.3d 87 (2d Cir. 2007) (requires strong inference of scienter; considers collective facts.)
- Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (U.S. 2007) (necessity that inferences be cogent and at least as compelling as opposing inferences.)
- Kalnit v. Eichler, 264 F.3d 131 (2d Cir. 2001) (motive is not required if conscious disregard is shown.)
- Stevelman v. Alias Research, Inc., 174 F.3d 79 (2d Cir. 1999) (disclosure timing; hindsight not enough to prove fraud.)
- Novak v. Kasaks, 216 F.3d 300 (2d Cir. 2000) (internal controls allegations must tie to specific misstatements.)
- Acito v. IMCERA Grp., Inc., 47 F.3d 47 (2d Cir. 1995) (stock sales alone are insufficient to plead scienter.)
- Freidus v. Barclays Bank PLC, 734 F.3d 132 (2d Cir. 2013) (earlier disclosures can reveal discoverable facts; not tolled indefinitely.)
- ECA, Local 134.IBEW Joint Pension Trust of Chicago v. JPMorgan Chase Co., 553 F.3d 187 (2d Cir. 2009) (GAAP violations or irregularities alone do not prove fraud absent intent.)
- Pace v. DiGuglielmo, 544 U.S. 408 (U.S. 2005) (equitable tolling requires reasonable diligence; extraordinary obstacles.)